Supplemental Fig S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• Zilovertamab vedotin shows specific plasma concentration-time profiles after administration, enhancing understanding of dosing efficacy.
• Participants receiving zilovertamab vedotin displayed distinct MMAE profiles, indicating the drug's pharmacokinetics in oncology settings.
• The phase 2 study explores therapeutic impacts of zilovertamab vedotin in a challenging patient population with few available options.
• Data from this study may help optimize future dosing strategies for metastatic solid tumor treatment.